Skip to main content
Map of Jps Health Network and nearby hospitalsTexas Health Harris Methodist Fort Worth, Fort WorthBaylor Scott and White All Saints Medical Center, Fort WorthTexas Health Harris Methodist Hospital Southwest F, Fort WorthTexas Health Huguley Hospital Fort Worth South, Fort WorthTexas Health Arlington Memorial Hospital, ArlingtonMedical City Fort Worth, Fort WorthBaylor Scott and White Surgical Hospital Fortworth, Fort WorthMedical City North Hills, North Richland HillsUsmd Hospital at Arlington L P, ArlingtonTexas Health Heart & Vascular Hospital Arlington, ArlingtonCook Childrens Medical Center, Fort WorthBaylor Scott and White Orthopedic and Spine Hospi, ArlingtonJps Health Network
This hospital (dark dot) and the nearest hospitals; dot size shows how many clinicians list each one. Select a dot to open that hospital.

Jps Health Network

Acute Care Hospitals · Government - Hospital District or Authority

1500 S Main St
Fort Worth, TX 76104

Call (817) 921-3431

  • Emergency services
  • Medicare overall rating: 4 of 5 stars

At a glance

Clinicians who list this hospital
794
Physicians (MD and DO)
479
Residents and fellows in training (full-time equivalents, fiscal year 2024)
229
Medical groups
15+

Find a doctor at Jps Health Network →

Quality and patient experience

Medicare overall rating (of 5)
4
Patient survey rating (of 5)
3
Patients who would definitely recommend it (national average 71%)
71%

Compared with the national rate

MeasuresBetterSameWorse
Deaths after treatment060
Safety of care (infections, complications)241
Readmissions and return visits071

Number of Medicare quality measures where this hospital’s rate is statistically better than, the same as (no different from), or worse than the national rate.

What patients said

  • Doctors communicated well 3 of 5 stars
  • Nurses communicated well 3 of 5 stars
  • Explained medicines 3 of 5 stars
  • Discharge information 3 of 5 stars
  • Clean 3 of 5 stars
  • Quiet at night 2 of 5 stars

From 2,442 patient surveys (HCAHPS), period ending 09/30/2025.

Medicare “birthing-friendly” hospital: takes part in a maternity care quality program and follows recommended safety practices.

Source: CMS Care Compare (Hospital General Information; Patient survey HCAHPS). Ratings describe the hospital overall, not individual doctors.

Medical groups whose clinicians work here

Number of each group’s clinicians who list this hospital.

Industry-funded research here

Drug and device companies reported $1,239,150 in research payments to this hospital in 2025 for 34 studies.

  • A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
    Novartis Pharmaceuticals Corporation · $282,523
  • A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
    Eli Lilly and Company · $107,442 · Active, not recruiting
  • Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
    AbbVie Inc. · $97,031 · Active, not recruiting
  • A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
    E.r. Squibb & Sons, L.l.c. · $83,430
  • Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC
    Genentech, Inc. · $76,644
  • An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
    E.r. Squibb & Sons, L.l.c. · $62,974
  • A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non …
    AstraZeneca Pharmaceuticals LP · $55,944
  • Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
    AbbVie Inc. · $55,922 · Completed
  • A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACT…
    Celgene Corporation · $41,164
  • A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
    Genentech, Inc. · $37,511
  • A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
    Merck Sharp & Dohme LLC · $34,852
  • A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neo…
    Merck Sharp & Dohme LLC · $34,812

From CMS Open Payments research payments to this hospital as a teaching hospital. Payments to affiliated universities or research foundations are reported under those names. All industry-funded trials →

Other hospitals in the same county

Sources: CMS Hospital General Information and Doctors and Clinicians Facility Affiliation (Care Compare), CMS certification number 450039. Counts are clinicians who list this hospital with Medicare; they include part-time and visiting clinicians and aren’t staff totals. Residents and beds are from the hospital’s Medicare cost report. Ratings are Medicare’s, not ours.